3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Squamous Cell Carcinoma of Head and Neck
3
Melanoma
3
Recurrence
2
Head and Neck Neoplasms
2
Carcinoma, Renal Cell
2
Triple Negative Breast Neoplasms
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Kidney Neoplasms
1
Glioma
1
Ependymoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Interventions
pembrolizumab
8
avelumab
6
fludarabine
3
Radiotherapy
3
Radiation
3
Cyclophosphamide
3
cemiplimab
2
atezolizumab
2
aldesleukin
2
Interleukin-2
2
Interferon-beta
2
ALT-803
2
talimogene laherparepvec
1
poly ICLC
1
pentetreotide
1
interferon gamma-1b
1
epacadostat
1
efineptakin alfa
1
durvalumab
1
cabozantinib
1
bempegaldesleukin
1
TTI-621
1
Paclitaxel
1
Nivolumab
1
Interferon-gamma
1
Influenza Vaccines
1
Immunotherapy
1
High-Intensity Focused Ultrasound Ablation
1
Carboxylesterase
1
B7-H1 Antigen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Carcinoma, Merkel Cell
×
bempegaldesleukin
×
Clear all
NCT03435640
2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2
Terminated
64 enrolled
22 charts